Objective-Matrix metalloproteinase (MMP)-2 is activated in aorta during endotoxemia and plays a role in the hypocontractility to vasoconstrictors. Calponin-1 is a regulator of vascular smooth muscle tone with similarities to troponin, a cardiac myocyte protein that is cleaved by MMP-2 in myocardial oxidative stress injuries. We hypothesized that calponin-1 may be proteolyzed by MMP-2 in endotoxemia-induced vascular hypocontractility. Methods and Results-Rats were given a nonlethal dose of bacterial lipopolysaccharide (LPS) or vehicle. Some rats were given the MMP inhibitors ONO-4817 or doxycycline. Six hours later, plasma nitrateϩnitrite increased Ͼ15-fold in LPS-treated rats, an effect unchanged by doxycycline. Both ONO-4817 and doxycycline prevented LPS-induced aortic hypocontractility to phenylephrine. LPS activated MMP-2 in the aorta by S-glutathiolation. Calponin-1 levels decreased by 25% in endotoxemic aortae, which was prevented by doxycycline. Calponin-1 and MMP-2 coimmunoprecipitated and both exhibited uniform cytosolic staining in medial vascular smooth muscle cells. In vitro incubation of calponin-1 with MMP-2 led to calponin-1 degradation and appearance of its cleavage product.
S epsis remains one of the most common causes of death worldwide. 1 Its cardiovascular manifestations include myocardial dysfunction and severe arterial hypotension caused in part by vascular hyporeactivity to vasoconstrictors. 2 Several mechanisms 3 including lipopolysaccharide (LPS)and interleukin-1␤-mediated activation of inducible nitric oxide (NO) synthase, excess biosynthesis of NO, 4, 5 and peroxynitrite (ONOO Ϫ ) 6, 7 in the vascular wall are important mediators of the vascular dysfunction in sepsis. ONOO Ϫ directly activates matrix metalloproteinases (MMPs), 8, 9 a group of zinc-dependent endopeptidases best known for their ability to degrade extracellular matrix proteins, causing vascular dysfunction and remodeling in many cardiovascular diseases. 10 -16 MMPs are synthesized as inactive zymogens in several cells, including vascular smooth muscle that express 72 kDa MMP-2 abundantly. 10 It is activated by proteolytic removal of the autoinhibitory propeptide domain 10 or, alternatively, by S-glutathiolation of a critical cysteine in this propeptide, on reaction with ONOO Ϫ and glutathione, resulting in 72 kDa S-glutathiolated MMP-2. 9 However, whether MMP-2 activation occurs by S-glutathiolation in the vasculature is unknown.
Studies have implicated MMPs and the beneficial effects of MMP inhibition in experimental models of sepsis. [17] [18] [19] [20] [21] [22] [23] MMP-2 plays an important role in LPS-induced vascular hypocontractility in rats. In vivo treatment with the MMP inhibitor doxycycline attenuated LPS-induced increase in vascular MMP-2 activity and protected against the loss of vascular contractile tone. 18 Doxycycline or another MMP inhibitor GM6001 also improved LPS-induced hypocontractility to phenylephrine in isolated aorta. 17 The mechanism by which MMPs contribute to this vascular hypocontractility remains unknown.
MMP-2 in particular is also an ubiquitous, intracellular protease that cleaves specific proteins inside cardiac myocytes to thereby reduce contractile function. 24, 25 MMP-2 activation in cardiac myocytes by oxidative stress results in the cleavage of targets to which it colocalizes including troponin I, 26 myosin light chain-1, 27 ␣-actinin, 28 and titin, 29 proteins essential for cardiac muscle contraction. MMP inhibitors improved contractile function in ischemic-reperfused rat hearts and prevented the proteolytic loss of these proteins. 26, 27, 29 These intracellular effects of MMP-2 in the heart under oxidative stress suggest that MMP-2 may also have intracellular targets in diseases such as sepsis associated with oxidative stress.
Calponin-1 is a 34 kDa actin-binding protein with regions of sequence homology to cardiac troponin I and T. 30 -32 It is located in the cytoskeleton and contractile apparatus of differentiated smooth muscle cells. 33 There are 3 isoforms of calponin: calponin-1 (h1 or basic), calponin-2 (h2 or neutral), and calponin-3 (h3 or acidic). Calponin-1 is implicated in the regulation of smooth muscle contraction by mediating intracellular signaling responses to some vasoconstrictors by acting as a contractile scaffold protein. 32, 34 This mechanism is based on results in aortic smooth muscle cells stimulated with phenylephrine, which showed calponin-1 connecting protein kinase C and ERK1/2 pathways to promote contractility. Although calponin-1 also inhibits the actin-activated myosin MgATPase, this action is abrogated by protein kinase C-catalyzed phosphorylation of calponin-1 35, 36 which may occur in sepsis. Calponin-1 knockout mice exhibit both reduced vasoconstriction and a diminished rise in mean arterial pressure in response to ␣-adrenergic agonists. 37 Thus, in theory, cleavage of calponin-1 would result in a decreased vascular contractile response. Although lower calponin-1 levels have been reported in animal models of traumatic brain injury and cardiovascular diseases associated with vascular dysfunction, 32, 38 no study has yet examined calponin-1 in vascular smooth muscle in endotoxemia or whether this protein may contribute to sepsis-induced vascular hypocontractility. Here we hypothesized that calponin-1 may be colocalized with and degraded by MMP-2 in the vasculature to contribute to endotoxemia-induced vascular hypocontractility.
Methods

Rat Endotoxemia
Male Sprague Dawley rats (250 -300 g) were injected with either a nonlethal dose of LPS (Salmonella typhosa, 4 mg/kg IP; Sigma) or pyrogen-free water vehicle (control; Sigma). Some rats were given the MMP inhibitors ONO-4817 (100 mg/kg by gavage, diluted in 0.5% carboxymethylcellulose) 2 hours prior to LPS or doxycycline (4 mg/kg IP, Sigma) 30 minutes after LPS. 18 Doxycycline preferentially inhibits MMP-2, -9, and -8 activities and is a much weaker inhibitor of MMP-1. 39, 40 ONO-4817 is a more selective MMP inhibitor with a K i in the nanomolar range for MMP-2 and MMP-9 and almost no inhibitory activity up to 100 mol/L against several other proteases. 41 Six hours after LPS rats were euthanized using an overdose of sodium pentobarbital (100 mg/kg, IP 
Assessment of Vascular Hypocontractility
Aortic rings 5 mm in length were mounted in organ baths for isometric tension recording. Rings were exposed to increasing concentrations of phenylephrine (10 Ϫ9 to 10 Ϫ5 mol/L) as previously described. 18
Western Blot Analysis, Coimmunoprecipitation Studies, and MMP-2 Activation
Calponin-1 protein levels were examined in aortic homogenates by Western blot. 18 To investigate whether LPS induces MMP-2 activation by S-glutathiolation, aortic homogenates were incubated without or with dithiothreitol (0.1, 0.3 or 1.0 mmol/L) and then coimmunoprecipitation analysis was performed with specific antibodies against glutathione and MMP-2 (online-only Data Supplement). Coimmunoprecipitation studies of MMP-2 with calponin-1 in aorta were also performed. For details, see online-only Data Supplement.
Immunohistochemistry and Confocal Microscopy
Aortae were fixed with 4% paraformaldehyde for 4 hours at room temperature and then cryoprotected in 30% sucrose in 0.1 mol/L sodium phosphate buffer overnight at 4°C. After that, cryoprotected aortae were vertically embedded in Tissue-Tek OCT compound and then frozen and serially cyrosectioned (5-m sections). Double-immunofluorescence with primary antibodies from different host species was performed. 42 For details, see online-only Data Supplement. Calponin-1 levels in aortic cryosections were obtained by quantification of fluorescence intensity/area using ImageJ software.
In Silico Analysis, In Vitro Degradation Assay, and Mass Spectrometry
Putative cleavage site motifs for MMP-2 (PVS2LRS, PEA2LRG, PEG2LRV, PAV2MTS and LAA2ITA, as shown by the arrows) were identified within the primary sequence of human calponin-1 using the SIM Alignment tool for protein sequences. To test whether calponin-1 is susceptible to proteolysis by MMP-2 in vitro, purified human recombinant calponin-1 was incubated with human recombinant MMP-2 at 37°C in 50 mmol/L Tris-HCl buffer. To verify that the resulting degradation products were in fact derived from calponin-1, they were digested with trypsin and analyzed by LC-MS/MS using a Thermo LTQ Orbitrap XL mass spectrometer and the MASCOT database to identify the protein (www.matrixscience.com). For details, see online-only Data Supplement.
Statistical Analysis
Results are expressed as means Ϯ SEM. Between-groups comparisons were assessed using either Student t test, 2 or one-way ANOVA followed by Tukey or Dunnett's posthoc tests, as appropriate. Pearson correlations and linear regression were calculated in all groups comparing aortic calponin-1 levels with plasma NO x Ϫ (GraphPad Prism 5.01 software). PϽ0.05 was considered significant.
Results
Signs of Endotoxemia and Plasma NO x ؊ levels
Six hours after LPS administration, rats developed marked symptoms of endotoxemia including lethargic behavior, piloerection, diarrhea, and porphyrin secretion from the snout and eyes. Treatment with either ONO-4817 or doxycycline did not ameliorate these symptoms. To further test whether rats were endotoxemic, plasma NO x Ϫ was measured. Table   Table. shows that NO x Ϫ in LPS-treated rats increased Ͼ15-fold in comparison to the control group (PϽ0.001). Doxycycline did not reduce the LPS-induced increase in NO x Ϫ levels, indicating that it did not interfere with inducible NO synthase activity.
MMP Inhibition Prevented LPS-Induced Aortic Hypocontractility to Phenylephrine
To test whether MMP inhibition protects against LPSinduced hypocontractility to vasoconstrictors, the contractility of isolated rat aortic rings to phenylephrine was assessed. Aortae from LPS rats contracted less well to phenylephrine (PϽ0.01 versus control) whereas either ONO-4817 or doxycycline significantly prevented LPS-induced hypocontractility (PϽ0.01, Figure 1 ).
LPS Enhanced MMP-2 S-Glutathiolation in Aorta
As a means to determine the mechanism of activation of MMP-2 in aorta, immunoblot analysis for MMP-2 of antiglutathione, but not control IgG 1 immunoprecipitates, showed 30% higher levels of S-glutathiolated 72 kDa MMP-2 in LPS aorta compared to control (PϽ0.05; Figure 2 ). As expected for S-glutathiolation reactions of proteins, 43 MMP-2 S-glutathiolation was reversed by dithiothreitol in a concentration-dependent manner. These results indicate that LPS enhances MMP-2 S-glutathiolation in aortae.
MMP Inhibition Prevented LPS-Induced Loss of Calponin-1 in Aorta
We determined whether MMP-mediated aortic hypocontractility in endotoxemia is related to calponin-1 proteolysis. Examination of LPS-treated rat aortae by Western blot revealed a 25% loss of 34 kDa calponin-1 protein (PϽ0.05 versus control, Figure 3A ). Although doxycycline did not alter the level of calponin-1 in control aortae, it prevented LPS-induced loss of calponin-1 (PϽ0.05, Figure 3A ). The extent of calponin-1 loss in aortae among the LPS-treated rats was variable; however the aortic level of calponin-1 correlated inversely with plasma NO x Ϫ in this group ( Figure 3B ), whereas no correlation existed between calponin-1 and NO x Ϫ levels in control, doxy or LPSϩdoxy groups ( Figure 3B ).
We also assessed calponin-1 levels in aortae by immunofluorescence. Six hours after LPS, calponin-1 staining was significantly less throughout the aortic medial smooth muscle when compared with controls (PϽ0.05, Figure 3C ). Doxycycline partially prevented LPS-induced loss of aortic calponin-1, which was associated with its better preservation in luminal smooth muscle.
Association of MMP-2 with Calponin-1 in Aorta
To test the possible association between MMP-2 and calponin-1 in aortae, we first performed coimmunoprecipitation studies using calponin-1 antibody followed by Western blot for MMP-2. Immunoblot analysis for MMP-2 of anticalponin-1, but not IgG immunoprecipitates, showed the presence of 72 kDa MMP-2, suggesting a strong association between these proteins ( Figure 4A ). Double-immunofluorescence confocal microscopy was also performed to examine this. Figure 4B shows that both proteins exhibited uniform cytosolic staining in vascular smooth muscle cells in the aortic wall and colocalized to each other in this compartment, strengthening the hypothesis that MMP-2 may proteolyse calponin-1 in aortic smooth muscle.
MMP-2 Cleaves Calponin-1 In Vitro
In silico mapping of putative MMP-2 cleavage sites within the amino acid sequence of human calponin-1 revealed sites in the troponin I-like/actin-binding region (Pro 154 -Glu 159) and in the second calponin repeat within the C-terminal domain (Gln 216 -Ala 221). This search was restricted to calponin-1 sites with at least 50% identity to 6 amino acids of different putative MMP-2 cleavage motifs ( Figure 5A ).
We also tested using either Coomassie Blue stained gels or Western blotting whether calponin-1 is susceptible to proteolysis by MMP-2 in vitro. Incubation of calponin-1 with human recombinant MMP-2 (100:1 molar ratio, 37°C) led to the complete loss of the 34 kDa calponin-1 band and the concomitant appearance of a 15 kDa degradation product at 2 hours. Inhibition of MMP activity with GM6001 significantly prevented calponin-1 degradation ( Figure 5B ). Troponin I was used as a positive control because it is effectively degraded by MMP-2 in vitro. 26 We found similar results when Western blot for calponin-1 was performed after its incubation with MMP-2 at 100:1 molar ratio for 2 hours (data not shown). Densitometric analysis showed the disappearance of the 34 kDa calponin-1 band and the simultaneous appearance of a 15 kDa degradation product at both 300:1 and 100:1 molar ratios ( Figure 5C ). Mass spectrometric analysis of the excised and trypsin-digested band of 15 kDa identified it as a mixture of 2 calponin-1 fragments because 17 peptides with coverage of 67% of the entire protein were identified with a MASCOT score of 2857 (see Table, in the online-only Data Supplement).
Discussion
MMP-2 is activated in the vascular wall during oxidative stress induced by endotoxemia and plays an important role in the resultant hypocontractility to vasoconstrictors. 17, 18 We evaluated here a potential mechanism by which MMP-2 contributes to this. We found that LPS treatment activates aortic MMP-2 by S-glutathiolation and that MMP-2 colocalizes with and degrades calponin-1 to contribute to endotoxemia-induced vascular hypocontractility, as this was reduced in rats given 2 chemically distinct MMP inhibitors, ONO-4817 or doxycycline. To our knowledge this is the first study showing an intracellular action of MMP-2 in vascular smooth muscle.
MMP-2 is recognized for its ability to degrade extra-and intracellular proteins and this effect contributes to cardiovascular dysfunction and remodeling in many diseases. 10 -12,24 A significant involvement of MMPs and the beneficial effects of their inhibition have been shown in experimental models of sepsis [17] [18] [19] [20] [21] [22] although proteolytic targets have not yet been identified. MMP-2 plays an important role in LPS-induced aortic hypocontractility in vivo and in vitro as its effects were completely prevented with either doxycycline or GM6001. 17, 18 Because doxycycline and GM6001 inhibit several MMPs, 39, 40 we here also tested ONO-4817 (K i in the nanomolar range for MMP-2 and -9 and almost no inhibitory activity up to 100 mol/L against several other proteases 41 ) as a further pharmacological control. ONO-4817 was also able to prevent LPS-induced aortic hypocontractility similar to the effect of doxycycline. Studies suggested that high concentrations of tetracyclines may decrease inducible NO synthase protein expression via destabilization of its mRNA 44, 45 resulting in a decrease of NO production. Here and consistent with previous work, 5 inducible NO synthase is upregulated in LPS-treated rats as we observed increased plasma NO X Ϫ levels. However, doxycycline did not reduce this elevation of NO x Ϫ . This indicates that the protective effect of MMP inhibition by doxycycline in our model of endotoxemia is independent of action on inducible NO synthase.
MMP-2 is localized within cardiac myocytes to specific subcellular organelles 46, 47 including the sarcomere, where it colocalizes with proteins of the contractile machinery including troponin I. 26 -29 MMP-2 degrades these proteins in cardiac muscle undergoing enhanced oxidative stress to cause impaired contractile function. 26 MMP inhibitors improved me-chanical function of hearts subjected to ischemia and reperfusion injury and prevented the proteolytic loss of these MMP-2 target proteins. 26, 27, 29 Based on these earlier studies in cardiac muscle, and because endotoxemia is also associated with enhanced oxidative stress and aortic hypocontractility, we investigated whether a troponin-like protein, calponin-1, is an intracellular target of MMP-2 in vascular smooth muscle during endotoxemia.
Calponin-1 is an actin-binding protein located in the cytoskeleton and contractile apparatus of differentiated smooth muscle cells. A strong association between MMP-2 and calponin-1 in vascular smooth muscle was demonstrated by both coimmunoprecipitation and confocal microscopy studies ( Figure  4A and 4B) . We showed using either Western blot or immunofluorescence that 6 hours of LPS treatment reduced calponin-1 levels in aorta, an effect that was abrogated by doxycycline ( Figure 3A and 3C) . The 3 known calponin isoforms contain a highly conserved N-terminal portion (which includes the calponin homology domain), a troponin I-like/actin-binding domain and 3 C-terminal repeats that differ among the 3 isoforms. 32, 48 Calponin-1 regulates smooth muscle contraction either by mediating intracellular signaling of vasoconstrictors by acting as a contractile scaffold protein, 32 or by inhibiting actinmyosin cross-bridge cycling, 35 which is alleviated by protein kinase C-catalyzed phosphorylation of calponin-1. 38 The scaffold mechanism is based on results in aortic smooth muscle cells stimulated with phenylephrine, which showed calponin-1 as an adaptor protein connecting protein kinase C and ERK1/2 path- ways to promote contractility. 32, 34 Mice containing a truncated form of the C-terminal of calponin-1, lacking the troponin I-like domain and the 3 C-terminal repeats, presented with both reduced vasoconstriction and a reduced vasopressor response to ␣-adrenergic agonists. 32, 37 MMP-2 activation is essential for its proteolytic effect both inside and outside the cell. MMP-2 activity is regulated at multiple levels including gene transcription, posttranslational modifications, and by interaction with its endogenous tissue inhibitors. 24 In addition to its activation by proteolysis, 72 kDa MMP-2 is also activated by ONOO Ϫ in the presence of glutathione without requiring proteolytic removal of its propeptide domain. 9 This results in active, 72 kDa S-glutathiolated MMP-2 which participates in oxidative stress injuries. 24 LPS increased the S-glutathiolation of 72 kDa MMP-2 in the aorta, an effect that was completely reversed by the reducing agent dithiothreitol. The LPS-induced increase in aortic ONOO Ϫ biosynthesis 6 is likely the means by which MMP-2 is activated in the aorta to trigger calponin-1 proteolysis and vascular hypocontractility. As plasma NO x Ϫ reflects increased NO and ONOO Ϫ biosynthesis in endotoxemia, [5] [6] [7] the resultant activation of MMP-2 led to calponin-1 proteolysis. Indeed there was a significant inverse correlation between plasma NO x Ϫ and aortic calponin-1 levels ( Figure 3B ). We speculate that following MMP-2 activation within vascular smooth muscle, it is also released from the cells as a protective mechanism to lessen the burden of intracellular proteolytic stress. However, it is unclear whether MMP-2 released from cells may continue to have other effects on vascular tone by degrading targets outside the cell. Our working model of this hypothesis is shown in Figure 6 . Although we suggest that MMP-2 contributes to LPS-mediated aortic hypocontractility by cleaving calponin-1, the proteolytic actions of other MMPs or other proteases cannot be entirely ruled out, especially because the inhibitors we used are not specific only for MMP-2. Because our study was performed in aortae, which have little impact in controlling the arterial blood pressure, future studies should also be carried out in resistance arteries.
We showed that MMP-2 cleaves calponin-1 in vitro resulting in a 15 kDa cleavage product which was prevented by an MMP inhibitor. By mass spectrometry we showed that this 15 kDa band contains 2 fragments of MMP-2-degraded calponin-1 (see Table in the online-only Data Supplement). In silico analysis of putative MMP-2 cleavage sites in human calponin-1 showed at least 2 sites with 50% identity in its troponin I-like/actin-binding (Pro 154 -Glu 159) and C-terminal (Gln 216 -Ala 221) domains. Cleavage at Lys 156 would generate 2 fragments of similar size: an N-terminal fragment of 17,704 Da and a C-terminal fragment of 15,484 Da, consistent with the mass spectrometric data. The C-terminal portion of calponin-1 seems to be important for its action on vascular smooth muscle contraction. We used the monoclonal rabbit calponin-1 (C-terminus) antibody to detect calponin-1 and observed, whether by Western blotting ( Figure  3A ) or by confocal microscopy (Figure 3C ), less of it in aortae of LPS-treated rats which was prevented by doxycycline. Similar results were obtained if either mouse monoclonal calponin-1 (full-length) or rabbit polyclonal calponin-1 (N-terminus) antibodies were used in the Western blot experiments (data not shown).
In conclusion, MMP-2 and calponin-1 are associated together in aortic vascular smooth muscle cells. MMP-2 is activated in vascular smooth muscle during endotoxemia by S-glutathiolation, which then proteolyses calponin-1 to contribute to LPS-induced hypocontractility, an effect abolished by MMP inhibitors. The intracellular actions of MMP-2 in vascular smooth muscle in health and disease, its other potential proteolytic targets, and the possibility of inhibitors specifically targeting MMP-2 as therapeutic agents for septic shock will be important future investigations. 
